Anatomic site and histological annotation of the primary tumor from which the cell line was derived.
Identifying and targeting cancer dependencies with small molecules
The Cancer Therapeutics Response Portal (CTRP) links genetic, lineage, and other cellular features of cancer cell lines to small-molecule sensitivity with the goal of accelerating discovery of patient-matched cancer therapeutics.
We generated an 'Informer Set' of 481 small-molecule probes and drugs that selectively target distinct nodes in cell circuitry and that collectively modulate a broad array of cell processes. We quantitatively measured the sensitivity of 860 deeply characterized cancer-cell lines to Informer Set compounds, and have undertaken analyses connecting sensitivity to cancer features, including mutations, gene expression, copy-number variation, and lineage. These analyses, and links to the underlying data, are provided openly on the CTRP.
The CTRP is a living resource for the biomedical research community that can be mined to develop insights into small-molecule mechanisms of action and novel therapeutic hypotheses, and to support future discovery of drugs matched to patients based on predictive biomarkers.
- 481 compounds X 860 CCLs
- correlations to copy-number and gene-expression data
- mutation data integrate CCLE and Sanger/MGH calls
- correlation and enrichment analysis on-the-fly
- box-whisker visualization in addition to enrichment heatmaps
- drill-down to scatter plots and concentration-response curves
- filter by lineage/subtype, growth mode
<< You are here
- 185 compounds X 242 CCLs
- pre-computed enrichment analysis and visualizations
- filter by lineage. CCLE mutation source, confounding factors
- 76,703 significant connections (q<0.01)